Cancer Genetics (CGIX) Misses Q2 EPS by 13c

Cancer Genetics (NASDAQ: CGIX) reported Q2 EPS of ($0.50), $0.13 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.13 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Diana Shipping drops bid for Genco after price demands spike to $36.91